Investor Presentaiton

Cendakimab: High-Affinity IL-13 Neutralizing Antibody for EoE Eosinophilic Esophagitis + Cendakimab EoE: Currently Enrolling Phase 3 study² • ⚫ Binds to IL-13 ligand IL-4 IL-13 IL-13 • ⚫ Blocks IL-13 binding to IL-13 IL-13Ra2 both IL-13Ra1 & IL-13Ra2 subunits Induction Phase Placebo 24 weeks Maintenance Phase Week 24 Co-Primary Endpoints 24 weeks Week 48 Secondary Endpoints • Tissue Inflammation Fibrosis and Remodeling EoE is a life altering disease affecting -700k¹ prevalent patients (combined U.S./EU5) Potentially differentiated MoA addressing a significant unmet need for a highly efficacious treatment that improves both inflammation & fibrosis/remodeling Cendakimab 360 mg SC QW Cendakimab 360 mg SC QW Co-primary (week 24): • Change in dysphagia days • Histologic response: eos ≤6/hpf Cendakimab 360 mg SC Q2W Key secondary (weeks 24 & 48): Histologic response: eos <15/hpf EREFS EOE-HSS • mDSD composite score Data anticipated in 2024 Ill Bristol Myers Squibb™ 1. Source: Decision Resources Group; BMS Internal Analysis; 2. NCT04753697 Not for Product Promotional Use 155

View entire presentation